FormuMax
Private Company
Funding information not available
Overview
FormuMax Scientific is a privately-held, revenue-generating company that serves as a strategic partner in drug delivery for pharmaceutical, biotech, cosmetic, and nutraceutical industries. Its core business model combines contract research services (CRS) with a direct-to-researcher e-commerce platform, offering a wide array of standardized and custom liposome-based products. With a focus on lipid nanoparticle (LNP) and exosome-mimicking technologies, the company leverages its expertise to enhance drug solubility, stability, and targeted delivery for challenging compounds, including small molecules, peptides, proteins, and nucleic acids like mRNA.
Technology Platform
Lipid-based nano-delivery platform specializing in liposomes, Stealth (PEGylated) liposomes, Lipid Nanoparticles (LNPs) for mRNA, and exosome-mimicking liposomes (Mikosome®). Expertise includes formulation for solubility enhancement, active loading, and targeted delivery of small molecules, peptides, proteins, and nucleic acids.
Opportunities
Risk Factors
Competitive Landscape
FormuMax competes in a fragmented landscape. It faces competition from large, diversified Contract Research Organizations (CROs like Lonza, Catalent, Charles River Labs) that offer formulation services as part of a broader suite, and from other specialized lipid nanoparticle companies (e.g., Acuitas Therapeutics, Genevant Sciences, Ethris). In the research product space, it competes with vendors like Avanti Polar Lipids and Sigma-Aldrich (MilliporeSigma). Its differentiation lies in its deep, focused expertise on liposomes, its hybrid service-product model, and its direct-to-researcher e-commerce platform.